^
Association details:
| Biomarker: | KRAS mutation + ER expression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
KRAS-mutated, ER-positive low-grade serous ovarian cancer: Unraveling an exceptional response mystery
Published date:
02/02/2021
Excerpt:
...a woman with aggressive estrogen receptor‐positive, KRAS‐mutated ovarian cancer who achieved a remarkable response to combination therapy with the MEK inhibitor (trametinib) and the aromatase inhibitor (letrozole), even though the patient had failed to respond to a combination of a PI3K inhibitor and different MEK inhibitor, as well as to trametinib and the estrogen modulator, tamoxifen, and to letrozole by itself.
DOI:
https://doi.org/10.1002/onco.13702
Source:
Title:
EP991 Exceptional response with combined anti-hormone and MEK inhibitor therapy in a patient with hormone receptor-positive ovarian cancer and isolated KRAS alteration. Implications for a precision medicine strategy
Excerpt:
The patient was subsequently started on monotherapy with letrozole; however, after 3 months of treatment, the tumor progressed. Letroizole was continued and trametinib was restarted...We report a patient with recurrent ovarian cancer with KRAS alteration and positive ER expression who demonstrated a remarkable response to combination therapy with a MEK inhibitor and aromatase inhibitor after failing treatment with the same MEK inhibitor in combination with a SERM.
Secondary therapy:
letrozole
Trial ID:
